Correlation Between Sonnet Biotherapeutics and Adial Pharmaceuticals

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Sonnet Biotherapeutics and Adial Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Sonnet Biotherapeutics and Adial Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Sonnet Biotherapeutics Holdings and Adial Pharmaceuticals, you can compare the effects of market volatilities on Sonnet Biotherapeutics and Adial Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Sonnet Biotherapeutics with a short position of Adial Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Sonnet Biotherapeutics and Adial Pharmaceuticals.

Diversification Opportunities for Sonnet Biotherapeutics and Adial Pharmaceuticals

0.59
  Correlation Coefficient

Very weak diversification

The 3 months correlation between Sonnet and Adial is 0.59. Overlapping area represents the amount of risk that can be diversified away by holding Sonnet Biotherapeutics Holding and Adial Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Adial Pharmaceuticals and Sonnet Biotherapeutics is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Sonnet Biotherapeutics Holdings are associated (or correlated) with Adial Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Adial Pharmaceuticals has no effect on the direction of Sonnet Biotherapeutics i.e., Sonnet Biotherapeutics and Adial Pharmaceuticals go up and down completely randomly.

Pair Corralation between Sonnet Biotherapeutics and Adial Pharmaceuticals

Given the investment horizon of 90 days Sonnet Biotherapeutics Holdings is expected to generate 1.15 times more return on investment than Adial Pharmaceuticals. However, Sonnet Biotherapeutics is 1.15 times more volatile than Adial Pharmaceuticals. It trades about -0.01 of its potential returns per unit of risk. Adial Pharmaceuticals is currently generating about -0.09 per unit of risk. If you would invest  159.00  in Sonnet Biotherapeutics Holdings on December 19, 2024 and sell it today you would lose (20.00) from holding Sonnet Biotherapeutics Holdings or give up 12.58% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Together 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Sonnet Biotherapeutics Holding  vs.  Adial Pharmaceuticals

 Performance 
       Timeline  
Sonnet Biotherapeutics 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Sonnet Biotherapeutics Holdings has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, Sonnet Biotherapeutics is not utilizing all of its potentials. The current stock price disarray, may contribute to short-term losses for the investors.
Adial Pharmaceuticals 

Risk-Adjusted Performance

Very Weak

 
Weak
 
Strong
Over the last 90 days Adial Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's forward indicators remain quite persistent which may send shares a bit higher in April 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.

Sonnet Biotherapeutics and Adial Pharmaceuticals Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Sonnet Biotherapeutics and Adial Pharmaceuticals

The main advantage of trading using opposite Sonnet Biotherapeutics and Adial Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Sonnet Biotherapeutics position performs unexpectedly, Adial Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Adial Pharmaceuticals will offset losses from the drop in Adial Pharmaceuticals' long position.
The idea behind Sonnet Biotherapeutics Holdings and Adial Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.

Other Complementary Tools

Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope